8.2.3.1.2. intralesional treatment. injection pharmacologically active agents directly penile plaques represents another treatment option. allows localised delivery pharmacological agent provides higher concentrations drug inside plaque. however, delivery compound target area difficult ensure, particularly dense calcified plaque present. calcium channel antagonists: verapamil nicardipine rationale intralesional use channel antagonists patients pd based vitro research . due use different dosing schedules contradictory results obtained published studies, evidence strong enough support clinical use injected channel blockers verapamil nicardipine results demonstrate meaningful improvement penile curvature compared placebo [900-905]. fact, studies perform direct statistical comparisons groups. collagenase clostridium histolyticum collagenase clostridium histolyticum (cch) chromatographically purified bacterial enzyme selectively targets collagen, primary component pd plaque [906-909]. intralesional injection cch used treatment pd since 1985. 2014 ema approved cch non-surgical treatment stable phase pd men palpable dorsal plaques abnormal curvature 30-90o non-ventrally located plaques present. administered healthcare professional experienced properly trained administration cch treatment pd . however, cch officially withdrawn european market manufacturer. despite evidence recommendations cch maintained guidelines completeness. original treatment protocol studies consists two injections 0.58 mg cch 24-72 hours apart every six weeks four cycles. data impress (investigation maximal peyronie´s reduction efficacy safety studies) ii ii studies , well post-approval trials , demonstrated efficacy safety treatment, summarised table 8.2 online appendix 5. average improvement curvature 34% compared 18.2% placebo group. three adverse events corporeal rupture surgically repaired. greatest chance curvature improvement curvatures 30° 60°, longer duration disease, iief > 17, calcification . 18.2% improvement baseline placebo arm also observed. findings raise questions regarding proposed role plaque injection penile modelling, regardless medication, improving outcomes men pd placebo modelling arm resulted relatively high curvature reduction compared treatment arm. conclusion impress ii studies cch improves pd physically psychologically . post hoc meta-analysis impress studies demonstrated better results patients curvatures < 60o, > 2 years onset, calcification plaque good erectile function . thereafter, modified short protocol consisting administration single (0.9 mg, one vial) injection per cycle distributed along three lines around point maximum curvature three cycles, separated 4-weekly intervals, proposed rapidly popularised replacing physician modelling multi-modal approach penile stretching, modelling ved home . results modified protocol comparable results impress trials appeared decrease cost duration treatment, although studies non-randomised. however, results explored prospective non-randomised multi-centre study . another large single-arm multi-centre clinical study using shortened protocol, longer pd duration, greater baseline pc basal dorsal plaque location identified clinically significant predictors treatment success . accordingly, nomogram developed predict treatment success cch pd showed patients longer pd duration, greater baseline penile curvature basal plaque location greater chance treatment success ; however, findings need externally validated. regarding safety concerns, pd patients treated cch experienced least one mild moderate adverse event localised penis (penile haematoma (50.2%), penile pain (33.5%), penile swelling (28.9%) injection site pain (24.1%), resolved spontaneously within 14 days injection . adverse reaction profile similar injection, regardless number injections administered. serious treatment-emergent adverse events (teaes) (0.9%) included penile haematoma corporeal rupture require surgical treatment. according impress data shortened protocol, prevent serious teaes men advised avoid sexual intercourse four weeks following injection. recent preliminary data suggest treatment acute phase disease effective safe [880,917-921]. conclusion, cch safe established treatment stable-phase disease wit recent evidence suggesting cch also role affecting progression active-phase disease. also noted large effect traction modelling controlled studies, whilst studies reporting modified protocols small numbers patients largely uncontrolled. therefore, patients counselled fully efficacy collagenase high cost treatment. suggested patients severe curvature may also benefit cch injections potential downgrading penile curvature: decrease curvature may allow penile plication procedure instead plaque incision grafting procedure, therefore avoiding negative impact erectile function plaque incision grafting. however, studies required validate initial findings . interferon α-2b intralesional injections (5x10^6 units ifn-α2b 10 ml saline every 2 weeks 12 weeks total six injections) significantly improved penile curvature, plaque size density, pain compared placebo. additionally, penile blood flow parameters benefited ifn-α2b . regardless plaque location, ifn-α2b effective treatment option. treatment ifn-α2b provides > 20% reduction curvature men pd, independent plaque location . given mild adverse effects, include sinusitis flu-like symptoms, effectively treated nsaids ifn-α2b injection, moderate strength data available, ifn-α2b currently recommended treatment stable-phase pd. steroids, hyaluronic acid botulinum toxin (botox) single-blind, placebo-controlled study intralesional administration betamethasone, statistically significant changes penile deformity, penile plaque size, penile pain erection reported . adverse effects include tissue atrophy, thinning skin immunosuppression . effect hyaluronic acid treatment patients pd investigated non-randomised study; intralesional injection hyaluronic acid compared intralesional verapamil acute phase pd significant improvement pain, curvature iief-15 observed . rct, oral administration hyaluronic acid combined intralesional injection found superior intralesional injection improvement 7.8±3.9 degrees curvature reduction plaque size 3.0 mm observed . single study evaluating intralesional botox injections men pd; therefore, insufficient evidence support treatment clinical practice . platelet rich plasma (prp) studies humans evaluated effect prp penile curvature, plaque size, pdq iief [930-935]. effect prp patients pd remains proven considered experimental. ongoing phase 2b randomized placebo-controlled crossover trial enrolled 25 patients planned target 80 men pd: first ongoing data nine patients treatment group vs eight placebo group showed difference curvature three months comparison baseline .